Literature DB >> 17988587

[Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance].

Xiao-Fei Wang1, Shuang-Long Yuan, Li Jiang, Xiao-Li Zhang, Shu-Fan Li, Yun Guo, Chun-Ling Wu, Juan-Juan Chen.   

Abstract

AIM: To investigate the changes of serum BAFF and IL-21 levels in the patients with systemic lupus erythematosus (SLE) and explore their clinical significance.
METHODS: The serum levels of BAFF and IL-21 were detected by enzyme-linked immunosorbent assay (ELISA).
RESULTS: The levels of serum BAFF and IL-21 in the patients with SLE were obviously higher than those in healthy control group. The BAFF level in the group of lupus nephritis (LN) with renal biopsy increased with pathologic aggravation and the IL-21 level in II, III, IV LN also increased, with the most obviously change in the type IV. The levels of BAFF and IL-21 obviously increased in SLE patients with Sjogren's syndrome (SS), but the levels of BAFF and IL-21 obviously tended to decrease in the patients after glucocorticosteroid treatment for a week, with the most significant decrease in BAFF. The changes of BAFF and IL-21 were related to major immune indexes in the patients with SLE. There was positive correlation between BAFF and IL-21 in IV LN.
CONCLUSION: The levels of serum BAFF and IL-21 level are increased in the patients with SLE. The dysfunction and synergistic effect of T and B lymphocytes play different roles in the patients with different organ damage and pathoprocess respectively.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988587

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  7 in total

1.  IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms.

Authors:  Vinh Nguyen; Irina Luzina; Horea Rus; Cosmin Tegla; Ching Chen; Violeta Rus
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis.

Authors:  Y Li; V K Rauniyar; W F Yin; B Hu; S Ouyang; B Xiao; H Yang
Journal:  Neurol Sci       Date:  2013-05-26       Impact factor: 3.307

3.  Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.

Authors:  Yumi Nakayama; Jolanta Kosek; Lori Capone; Eun Mi Hur; Peter H Schafer; Garth E Ringheim
Journal:  J Immunol       Date:  2017-08-28       Impact factor: 5.422

4.  IL-21-stimulated human plasmacytoid dendritic cells secrete granzyme B, which impairs their capacity to induce T-cell proliferation.

Authors:  Julien J Karrich; Loes C M Jachimowski; Maho Nagasawa; Angela Kamp; Melania Balzarolo; Monika C Wolkers; Christel H Uittenbogaart; S Marieke van Ham; Bianca Blom
Journal:  Blood       Date:  2013-02-13       Impact factor: 22.113

5.  Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands.

Authors:  Kwi Young Kang; Hyun-Ok Kim; Seung-Ki Kwok; Ji Hyeon Ju; Kyung-Su Park; Dong-Il Sun; Joo Yeon Jhun; Hye Jwa Oh; Sung-Hwan Park; Ho-Youn Kim
Journal:  Arthritis Res Ther       Date:  2011-10-26       Impact factor: 5.156

Review 6.  Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?

Authors:  Matthieu Sawaf; Hélène Dumortier; Fanny Monneaux
Journal:  J Immunol Res       Date:  2016-08-22       Impact factor: 4.818

7.  Circulating TFH subset distribution is strongly affected in lupus patients with an active disease.

Authors:  Carole Le Coz; Aurélie Joublin; Jean-Louis Pasquali; Anne-Sophie Korganow; Hélène Dumortier; Fanny Monneaux
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.